By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


UCB, Inc. 

1950 Lake Park Drive

Smyrna  Georgia  30080  U.S.A.
Phone: 770-870-7500 Fax: 770-970-8859


At UCB, everything we do starts with a simple question: “How will this make a difference to the lives of people living with severe diseases?” We have a passionate, long-term commitment to discovering and developing innovative medicines that transform the lives of people living with severe diseases. We do that by connecting with patients and their families around the world living with the physical and social burdens of severe disease. Those connections offer new perspectives, drive innovation, and offer the hope of a new generation of therapies that are helping to transform lives.

With a team of approximately 7,500 employees and operations in more than 40 countries, we are a global biopharmaceutical company investing more than a quarter of our revenue in cutting-edge scientific research to meet unmet patient needs. Global headquarters are in Brussels, Belgium, with U.S. headquarters in Atlanta, Georgia. Additional U.S. UCB sites include global clinical development at our Research Triangle Park, North Carolina campus (UCB Biosciences, Inc.), and research supporting UCB’s pipeline in Cambridge, Massachusetts (UCB Research, Inc.).

Key Statistics

Ownership: Public

Web Site: UCB, Inc.
Symbol: UCB

Company News
UCB, Inc. (UCBJF.PK) Release: Results From CRIB Study On CIMZIA (Certolizumab Pegol) Demonstrate Minimal To No Placental Transfer Of Drug From Mother To Infant During Third Trimester Of Pregnancy 6/14/2017 7:19:49 AM
UCB, Inc. (UCBJF.PK) Selects Medidata Solutions, Inc. Clinical Cloud To Support Patient-Centric Drug Development 4/26/2017 6:28:41 AM
1CellBiO Announces Collaboration Agreement With UCB, Inc. (UCBJF.PK) 4/11/2017 9:04:57 AM
Argentum Persists In Challenging The "Evergreening" Patent On UCB, Inc. (UCBJF.PK)'s VIMPAT 3/24/2017 6:59:53 AM
UCB, Inc. (UCBJF.PK) Release: First CIMZIA (Certolizumab Pegol) Study Of Its Kind Showed Minimal To No Transfer Of Drug From Mother's Plasma To Breast Milk 3/6/2017 7:48:35 AM
Amgen (AMGN) And UCB, Inc. (UCBJF.PK) Announce Submission Of Application For Investigational Osteoporosis Medication Romosozumab In Japan 12/20/2016 9:13:10 AM
UCB, Inc. (UCBJF.PK) Release: The Lancet Publishes First Head-To-Head Study Of CIMZIA (Certolizumab Pegol) And Humira (Adalimumab) In Bio-Naïve Rheumatoid Arthritis Patients 11/15/2016 10:22:38 AM
MRC Technology, UCB, Inc. (UCBJF.PK) And University of Leicester Collaborate To Form Antibody-Assisted Structure-Based Drug Discovery Consortium 11/8/2016 10:31:36 AM
UCB, Inc. (UCBJF.PK) Release: Certolizumab pegol (Cimzia) AutoClicks Prefilled Pen - A New Self-Injection Device Designed In Collaboration With Patients And Good Grips - Is Now Available In The UK On The NHS[1] 10/25/2016 9:18:41 AM
Evotec AG (EVTG.F) And UCB, Inc. (UCBJF.PK) Sign Multi-Year CNS Pharmacology Agreement 10/20/2016 1:28:19 PM